Market Overview

UPDATE: JMP Securities Reiterates On Navidea Biopharmaceuticals On Pipeline Restructuring

Share:

In a report published Monday, JMP Securities analyst Michael G. King reiterated a Market Outperform rating on Navidea Biopharmaceuticals (NYSE: NAVB), but lowered the price target from $5.00 to $3.00.

In the report, JMP Securities noted, “Navidea Biopharmaceuticals reprioritizes its pipeline away from Alzheimer's and Parkinson's candidates to focus on the Lymphoseek launch; reaffirming our Market Outperform rating, but lowering our price target from $5 to $3. As detailed on the conference call, Navidea intends to wind down development of NAV4694 and NAV5001 – diagnostic detection candidates for Alzheimer's and Parkinson's diseases, respectively – in an effort to preserve cash and avert shareholder dilution through equity financing. Concurrent with this announcement was a change in leadership, with Dr. Michael Goldberg now serving as interim CEO (replacing Dr. Mark Pykett).

"In our view, the anticipated benefit to cash flow from these changes, while important near term, fall short of off-setting the value attributed to the developing pipeline on an NPV basis. As such, we are decreasing our year-end price target for NAVB shares from $5 to $3, based on DCF ($3.69) and SOTP ($3.05) valuation methodologies.”

Navidea Biopharmaceuticals closed on Friday at $1.39.

Latest Ratings for NAVB

DateFirmActionFromTo
Aug 2020HC Wainwright & Co.MaintainsBuy
May 2020HC Wainwright & Co.MaintainsBuy
Mar 2020H.C. WainwrightReiteratesBuy

View More Analyst Ratings for NAVB
View the Latest Analyst Ratings

 

Related Articles (NAVB)

View Comments and Join the Discussion!

Posted-In: JMP Securities Michael G. KingAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com